Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Teng

Showing results (371-380 of 388) with videos related to

Pageof 39
Sort By:
Cell Reports|May 13, 2026
HOXD11-NMDAR signaling drives neuroendocrine prostate cancer and enables potential therapeutic intervention as a target of memantineTiange Wu, Song Tan, Likai Mao, et al.
European Radiology Experimental|June 16, 2026
TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysisRong Ding, Xiao-Yang Xu, Rui-Bao Liu, et al.
The Lancet. Oncology|April 19, 2014
Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trialHai-Dong Zhu, Jin-He Guo, Ai-Wu Mao, et al.
International Journal of Surgery (London, England)|April 11, 2023
Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trialJian Lu, Jin-He Guo, Jian-Song Ji, et al.
Journal of Hepatology|January 15, 2018
Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trialHai-Dong Zhu, Jin-He Guo, Ming Huang, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2026
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II TrialHai-Dong Zhu, Wei-Jun Fan, Chang Zhao, et al.
Clinical and Molecular Hepatology|July 11, 2024
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)Chuan Liu, Hong You, Qing-Lei Zeng, et al.
Med (New York, N.Y.)|May 22, 2025
DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus populationChuan Liu, Jie Shen, Jie Li, et al.
Eclinicalmedicine|February 18, 2026
Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation studyJian-Jian Chen, Zhi-Cheng Jin, Jia-Wei Zhou, et al.
Pageof 39

Showing results (371-380 of 388) with videos related to

Sort By:
Pageof 39
Cell Reports|May 13, 2026
HOXD11-NMDAR signaling drives neuroendocrine prostate cancer and enables potential therapeutic intervention as a target of memantineTiange Wu, Song Tan, Likai Mao, et al.
European Radiology Experimental|June 16, 2026
TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysisRong Ding, Xiao-Yang Xu, Rui-Bao Liu, et al.
The Lancet. Oncology|April 19, 2014
Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trialHai-Dong Zhu, Jin-He Guo, Ai-Wu Mao, et al.
International Journal of Surgery (London, England)|April 11, 2023
Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trialJian Lu, Jin-He Guo, Jian-Song Ji, et al.
Journal of Hepatology|January 15, 2018
Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trialHai-Dong Zhu, Jin-He Guo, Ming Huang, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2026
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2026
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II TrialHai-Dong Zhu, Wei-Jun Fan, Chang Zhao, et al.
Clinical and Molecular Hepatology|July 11, 2024
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)Chuan Liu, Hong You, Qing-Lei Zeng, et al.
Med (New York, N.Y.)|May 22, 2025
DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus populationChuan Liu, Jie Shen, Jie Li, et al.
Eclinicalmedicine|February 18, 2026
Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation studyJian-Jian Chen, Zhi-Cheng Jin, Jia-Wei Zhou, et al.
Pageof 39